Filtered By:
Drug: Actos
Education: Study

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 72 results found since Jan 2013.

Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
Conclusions -In IRIS, with surveillance and dose adjustments, pioglitazone did not increase risk of HF, and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. The risk of HF with pioglitazone was not modified by baseline HF risk. The IRIS experience may be instructive for maximizing the net benefit of this therapy. Clinical Trial Registration -URL: www.clinicaltrials.gov Unique identifier: NCT00091949. PMID: 29934374 [PubMed - as supplied by publisher]
Source: Circulation - June 22, 2018 Category: Cardiology Authors: Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN, IRIS Investigators Tags: Circulation Source Type: research

Efficacy of Lower Doses of Pioglitazone after Stroke or Transient Ischemic Attack In Patients with Insulin Resistance
CONCLUSIONS: Lower doses of pioglitazone appear to confer much of the benefit with less adverse effects than the full dose. Further study is needed to confirm these findings so that clinicians may optimize dosing of this secondary prevention strategy in stroke patients. This article is protected by copyright. All rights reserved.PMID:35253334 | DOI:10.1111/dom.14687
Source: Atherosclerosis - March 7, 2022 Category: Cardiology Authors: J David Spence Catherine Viscoli Walter N Kernan Lawrence H Young Karen Furie Ralph DeFronzo Muhammad Abdul-Ghani Paresh Dandona Silvio E Inzucchi Source Type: research

New front opens in battle against stroke
Medical scientists have vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study, researchers show that pioglitazone, a member of the insulin-sensitizing class of medications called thiazolidinediones, reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.
Source: ScienceDaily Headlines - February 25, 2016 Category: Science Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
WEDNESDAY, Feb. 17, 2016 -- The diabetes drug Actos (pioglitazone) appears to protect people who've already had a stroke from suffering a second stroke, a new study finds. Along with standard treatment after a stroke -- including blood thinners, and...
Source: Drugs.com - Daily MedNews - February 17, 2016 Category: Journals (General) Source Type: news

Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case –control study
Pioglitazone use is known to be associated with a reduced risk of recurrent stroke in patients with diabetes mellitus (DM) who have a history of stroke. However, it is unclear whether this benefit extends to p...
Source: Cardiovascular Diabetology - July 27, 2021 Category: Cardiology Authors: Junghee Ha, Dong-Woo Choi, Keun You Kim, Chung Mo Nam and Eosu Kim Tags: Original investigation Source Type: research

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Ischemic stroke patients with diabetes are at high risk for recurrent stroke and cardiovascular complications. Pioglitazone, a type of thiazolidinedione, has been shown to reduce cardiovascular complications i...
Source: Cardiovascular Diabetology - May 5, 2023 Category: Cardiology Authors: Joonsang Yoo, Jimin Jeon, Minyoul Baik and Jinkwon Kim Tags: Research Source Type: research

Pioglitazone and PPAR- γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
Peroxisome proliferator-activated receptor- γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are ad...
Source: Cardiovascular Diabetology - January 7, 2020 Category: Cardiology Authors: Chi-Hung Liu, Tsong-Hai Lee, Yu-Sheng Lin, Pi-Shan Sung, Yi-Chia Wei and Yan-Rong Li Tags: Original investigation Source Type: research

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study
Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare. Thus, we...
Source: Cardiovascular Diabetology - June 20, 2020 Category: Cardiology Authors: Yi-Chih Hung, Lu-Ting Chiu, Hung-Yu Huang and Da-Tian Bau Tags: Original investigation Source Type: research

PPAR agonists for the treatment of cardiovascular disease in patients with Diabetes
Conclusions: According to this study, Pioglitazone treatment in type 2 diabetes patients and hypersensitive Ischemic stroke patients is linked to minor ischemic stroke which is recurrent in Asian people. Pioglitazone and the telmisartan treatment have an increasing pleiotropic effect related to the higher PPAR- gamma effects. Further research needs to be conducted with the PPAR mechanism ' s details to confirm the PPAR effect on Ischemic stroke treatment. [Ethiop. J. Health Dev. 2021; 35(3): 249-257]Keywords: PPAR agonist, Dyslipidaemia, Thiazolidinediones, Type 2 diabetes, Pioglitazone, PPAR-alpha, PPAR-gamma, Insulin resistance, Alecardio.
Source: Ethiopian Journal of Health Development - November 25, 2021 Category: African Health Authors: Zheng Xia, Guo Lixia, Zhang Zhijun Source Type: research

Diabetes drug may prevent recurring strokes
This study was supported by the NIH's National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Medicine and Health - February 17, 2016 Category: Global & Universal Source Type: news

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia
In this issue ofJAMA Neurology, Spence et al discuss the effect of pioglitazone, an insulin-sensitizing agent that has been shown to reduce the risk of recurrent stroke and myocardial infarction in patients with insulin resistance, in patients with prediabetes. Prediabetes was defined according to the American Diabetes Association criteria, ie, a hemoglobin A1c level of 5.7% to 6.4% or a fasting plasma glucose level of 100 to 125 mg/dL. Data were taken from the Insulin Resistance Intervention after Stroke (IRIS) study, an international randomized clinical trial performed in patients with previous stroke or transient ischem...
Source: JAMA Neurology - February 7, 2019 Category: Neurology Source Type: research

Mild traumatic brain injury increases vulnerability to cerebral ischemia in mice
Exp Neurol. 2021 May 13:113765. doi: 10.1016/j.expneurol.2021.113765. Online ahead of print.ABSTRACTRecent studies have reported that TBI is an independent risk factor for subsequent stroke. Here, we tested the hypothesis that TBI would exacerbate experimental stroke outcomes via alternations in neuroimmune and neurometabolic function. We performed a mild closed-head TBI and then one week later induced an experimental stroke in adult male mice. Mice that had previously experienced TBI exhibited larger infarcts, greater functional deficits, and more pronounced neuroinflammatory responses to stroke. We hypothesized that impa...
Source: Experimental Neurology - May 16, 2021 Category: Neurology Authors: Zachary M Weil Kate Karelina Bailey Whitehead Ruth Velazquez-Cruz Robin Oliverio Mark Pinti Divine C Nwafor Samuel Nicholson Julie A Fitzgerald John Hollander Candice M Brown Ning Zhang A Courtney DeVries Source Type: research